Condition (MeSH)
Post-Cardiac Arrest Syndrome
ClinicalTrials.gov lists 30 trials for Post-Cardiac Arrest Syndrome or a narrower condition beneath it. Invero Pharma, Inc. has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
30 of the 30 trials are tagged with Post-Cardiac Arrest Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Post-Cardiac Arrest Syndrome trials start? (14)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 5 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 3 |
| 2020 | 3 |
| 2019 | 2 |
| 2017 | 1 |
| 2016 | 3 |
| 2015 | 1 |
Showing 10 of 14 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Post-Cardiac Arrest Syndrome trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 3 |
| Phase 4 | 1 |
| Not applicable | 9 |
| Observational | 14 |
How many Post-Cardiac Arrest Syndrome trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 6 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 2 |
| Completed | 12 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Post-Cardiac Arrest Syndrome trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Invero Pharma, Inc. | 1 |
Which drugs are being tested for Post-Cardiac Arrest Syndrome? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| INFLIXIMAB | 1 |
| Thiamine | 1 |
| Vitamin C | 1 |
| Xenon | 1 |
| METHYLPREDNISOLONE | 1 |
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Cyclosporine 0.05% | 1 |
| IM olanzapine | 1 |
| Dexamethasone/Dexamethasone acetate | 1 |
| The combined supplement of Ascorbic acid, Thiamine, and Cortisol | 1 |
| Sodium chloride injection USP, 0.9% (placebo) | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Post-Cardiac Arrest Syndrome? (11)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Cytokine hemoadsorption with CytoSorb<sup>®</sup> in post-cardiac arrest syndrome, a pilot randomized controlled trial. | Critical care (London, England) | 2023 | Yes |
| The inflammatory response is related to circulatory failure after out-of-hospital cardiac arrest: A prospective cohort study. | Resuscitation | 2022 | Yes |
| Cytokine adsorption in patients with post-cardiac arrest syndrome after extracorporeal cardiopulmonary resuscitation (CYTER) - A single-centre, open-label, randomised, controlled trial. | Resuscitation | 2022 | Yes |
| Outcome Related to Level of Targeted Temperature Management in Postcardiac Arrest Syndrome of Low, Moderate, and High Severities: A Nationwide Multicenter Prospective Registry. | Critical care medicine | 2021 | Yes |
| An exploratory assessment of serum biomarkers of post-cardiac arrest syndrome in children. | Resuscitation | 2021 | Yes |
Showing 5 of 11 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.